Literature DB >> 11793446

Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer.

Jennifer I Swalwell1, Cathy D Vocke, Youfeng Yang, Jonathan R Walker, Lynette Grouse, Stuart H Myers, John W Gillespie, David G Bostwick, Paul H Duray, W Marston Linehan, Michael R Emmert-Buck.   

Abstract

Loss of the short arm of chromosome 8 is a common event in prostatic neoplasms. Previous studies indicate that there may be up to three separate tumor suppressor genes on chromosome arm 8p, based on patterns of allelic loss. The responsible gene or genes have yet to be identified. In the present study, we used laser-capture microdissection of primary human prostate tumors and 17 microsatellite markers across chromosome band 8p21 to determine a minimal deletion interval. From an initial set of 120 cases, three tumors contained overlapping interstitial deletions on chromosome band 8p21. The three cases define an internally consistent minimal candidate tumor suppressor gene interval of approximately two megabases. Published 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11793446     DOI: 10.1002/gcc.10015

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  19 in total

1.  Nkx3.1 functions as para-transcription factor to regulate gene expression and cell proliferation in non-cell autonomous manner.

Authors:  Jian Zhou; Li Qin; Jean Ching-Yi Tien; Li Gao; Xian Chen; Fen Wang; Jer-Tsong Hsieh; Jianming Xu
Journal:  J Biol Chem       Date:  2012-03-31       Impact factor: 5.157

2.  NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage.

Authors:  Cai Bowen; Tian Zheng; Edward P Gelmann
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

3.  Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer.

Authors:  Pamela L Paris; Matthias D Hofer; Giancarlo Albo; Rainer Kuefer; Juergen E Gschwend; Richard E Hautmann; Jane Fridyland; Jeffrey Simko; Peter R Carroll; Mark A Rubin; Colin Collins
Journal:  Neoplasia       Date:  2006-12       Impact factor: 5.715

4.  Mystique is a new insulin-like growth factor-I-regulated PDZ-LIM domain protein that promotes cell attachment and migration and suppresses Anchorage-independent growth.

Authors:  Gary Loughran; Nollaig C Healy; Patrick A Kiely; Merei Huigsloot; Nancy L Kedersha; Rosemary O'Connor
Journal:  Mol Biol Cell       Date:  2005-01-19       Impact factor: 4.138

5.  CRISPR/Cas9-Mediated Point Mutation in Nkx3.1 Prolongs Protein Half-Life and Reverses Effects Nkx3.1 Allelic Loss.

Authors:  Cai Bowen; Maho Shibata; Hailan Zhang; Sarah K Bergren; Michael M Shen; Edward P Gelmann
Journal:  Cancer Res       Date:  2020-09-17       Impact factor: 12.701

6.  Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer.

Authors:  Erin Muhlbradt; Jing Ma; Gianluca Severi; Elizabeth Ortner; Vanessa Hayes; Hoa N Hoang; Meir Stampfer; Graham Giles; Michael Pollak; Edward P Gelmann
Journal:  Genes Cancer       Date:  2013-11

7.  NF-κB and cancer: a paradigm of Yin-Yang.

Authors:  Gutian Xiao; Jing Fu
Journal:  Am J Cancer Res       Date:  2010-12-06       Impact factor: 6.166

8.  NKX3.1 is regulated by protein kinase CK2 in prostate tumor cells.

Authors:  Xiang Li; Bin Guan; Sam Maghami; Charles J Bieberich
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

9.  Interactions of the acidic domain and SRF interacting motifs with the NKX3.1 homeodomain.

Authors:  Jeong Ho Ju; Jin-Soo Maeng; Duck-Yeon Lee; Grzegorz Piszczek; Edward P Gelmann; James M Gruschus
Journal:  Biochemistry       Date:  2009-11-10       Impact factor: 3.162

10.  PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation.

Authors:  Pengrong Yan; Jing Fu; Zhaoxia Qu; Shirong Li; Takashi Tanaka; Michael J Grusby; Gutian Xiao
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.